Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle shortages of ADHD medication.

The resilience of the United Kingdom’s supply chains is a key priority, and we are committed to helping build long term supply chain resilience for medicines. The Department works in partnership with industry, the National Health Service, and the wider health system to help ensure the continuity of the supply of medical products, including for attention deficit hyperactivity disorder (ADHD) medicines. These issues are often global in nature. We monitor and manage medicine supply issues at a national level, so that stocks remain available to meet regional and local demand, and therefore there are no specific measures for the West Midlands.

As a result of intensive work, some issues with ADHD medicines have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, and guanfacine prolonged-release tablets are now available.

However, whilst the supply of methylphenidate prolonged-release tablets has improved, issues still persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support the continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the UK market.

We are supporting an ADHD taskforce that NHS England has established to examine ADHD service provision. The taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to help provide a joined-up approach in response to concerns around rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.

The Department has worked with NHS specialists to develop advice on prescribing alternative ADHD medications. We expect that ADHD service providers should follow this guidance and offer rapid responses for urgent advice, especially for high-risk patients. To aid decision-making at the point of the prescribing and dispensing of ADHD medicines, we continue to update a list of available ADHD products on the Specialist Pharmacy Service website.